BioAlliance has hired Louis Kayitalire as head of research and development.
Previously in the leadership teams for Eli Lilly and Mristol Myers Squibb, Kayitalire most recently worked for Cephalon, where he was VP of clinical research for oncology, immunology, inflammation, CNS (central nervous system) and pain in Europe.
In his new role he will take charge of development strategy from preclinical phases to registration.
Judith Greciet, CEO, said: “He is joining the company at a key stage of its strategic deployment in oncology, today with three products in an active development phase and determining milestones to come in the next months. I am sure that thanks to his large experience combined with his open and enthusiastic personality, he will rapidly and efficiently succeed in integrating the team.”
Cangene has named Jeff Lamothe the new CFO.
Currently in the same role for Smith Carter Architects and Engineers Incorporated, and before that the CFO for a kitchen supplies company, this is Lamothe’s first move into the pharma business.
CEO John Sedor said: "We believe that Jeff will add significant value to our organisation and the senior management team as we continue to position the company for future growth.
"He is a proven leader with the skills and experience necessary to help Cangene execute on its strategy.”
Dipak Panigrahi has joined Sucampo as VP of medical affairs.
In his new role, he will establish a medical science liaison (MSL) and will take charge of key opinion leader development and providing advice on clinical trial design and development.
Previously, Panigrahi worked for contract pharmaceutical support firm Provision Pharmaceutical Consulting.
Ryuji Ueno, CEO said: “As a company that remains particularly focused on scientific advancements and research, our MSL team will be a key value driver in communicating those messages to the medical community.
“Our planned launch of RESCULA, later this year in the US, will be one of our major events for Sucampo and will move us closer to becoming a fully integrated pharmaceutical company that discovers, develops, manufactures and commercialises its own products.”
Consort Medical has drafted in Steve Crummett and Ian Nicholson as non-executive directors, as well as Richard Cotton as group finance director.
Crummett – currently group finance director of Filtrona – and former Chroma Therapeutics CEO Nicholson, replace retirees Chris Banks, and Jim Dick who will abdicate this August.
Chartered management accountant Cotton replaces Toby Woolrych, who will leave the company at the end of this month.
Chairman Peter Fellner said: "We warmly welcome the appointment of Steve, Ian and Richard to the Board. They all bring substantial and wide ranging experience and we look forward to working with them as we grow Consort for the benefit of our stakeholders.”
Chris Claxton has become marketing manager of discovery products for Horizon Discovery.
He joins from the SAFC where he was market segment manager responsible for the industrial cell culture offering.
In his new role, Claxton will be responsible for the core products and services based on the proprietary proprietary rAAV technology for precision genome editing and functional genomics.
CEO Darrin Disley said: “As we expand upon the range of markets and applications that the company will be addressing, Chris will play a key role in ensuring that customers are aware of the unique benefits that working with Horizon can bring to them.”